Navigation Links
Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
Date:2/15/2011

I trial). Collectively, the drugs forecast in this report for breast cancer are forecast to achieve $1.1 billion in sales by 2019.

There are currently 41 drugs in the pipeline for ovarian cancer, of which 10 are in late-phase development. Collectively, the drugs in late-phase development for ovarian cancer profiled in this report are forecast to achieve $1.8bn in sales by 2019.

R&D interest in cervical cancer is limited compared with other cancers and as a result there is a lack of novel drug candidates in late-phase development. Despite poor outcomes and prognoses for late-stage patients, recent focus has been directed towards preventative strategies rather than treatment.

Key reasons to purchase this research

Identify key drugs within the breast and ovarian cancer pipelines based on sales forecasts and Datamonitor drug assessment Characterize unmet needs within breast, ovarian and cervical cancers and assess the potential for pipeline products to fulfill them Assess the shifting breast, ovarian and cervical cancer market dynamics and how future treatment will incorporate pipeline products

To order this report:

: Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market
2. Reportlinker Adds Amphotericin B - Comprehensive patent search
3. Reportlinker Adds Therapeutic Proteins to 2014
4. Reportlinker Adds Biochips - Products, Applications, Technologies and End-Use Markets Growth Analysis, 2009-2015
5. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
6. Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
7. Reportlinker Adds The 2011 Immunoprotein Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment
8. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers
9. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
10. Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration
11. Reportlinker Adds Vaccine Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... today announced a collaboration with University of California, ... test ImmunoPulse™ IL-12 as an immunotherapy in dogs ... the canine study are to advance the understanding ... and validate key clinical biomarkers. ...
(Date:6/1/2015)... Calif. , June 1, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... a Phase 2 clinical trial of AST-VAC1 in ... leukemia (AML). AST-VAC1 is the Company,s autologous (using ... cancer vaccine. AML is the most common form ...
(Date:5/31/2015)... BARCELONA, Spain , June 1, 2015 /PRNewswire/ ... company dedicated to rare diseases, has selected Veeva ... across sales, marketing, and medical. A complete solution, ... data, multichannel interactions, and compliant content to provide ... and effective commercial execution.      (Logo: ...
(Date:5/31/2015)... Grow Med University (GMU) is a free, ... at their own pace and dip into the rich ... both scientific and other informative articles, to hone their ... harvest yet! , The medical marijuana industry is ... in the U.S. and a slew of other businesses ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3Grow Med University: a Brand New Online Hydroponics Course 2
... ATLANTA, Sept. 24 GeoVax Labs, Inc. ... company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), ... in the recently completed Phase 3 trial in Thailand of ... for Infectious Diseases. The completed study represents the first HIV/AIDS ...
... NEW YORK, Sept. 24 Reportlinker.com announces that a ... , Stem Cell Therapeutics Markets ... Political and business events presage change for stem cell ... lift federal funding restrictions on stem-cell research. The U.S. Congress has ...
... , , , ... CALP ), a leading provider of tools and services ... of XenoLight Rediject reagents at the World Molecular Imaging ... in an expanding range of XenoLight reagents for Caliper,s IVIS optical ...
Cached Biology Technology:Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 2Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 3Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 4Reportlinker Adds Stem Cell Therapeutics Markets Report 2Reportlinker Adds Stem Cell Therapeutics Markets Report 3Reportlinker Adds Stem Cell Therapeutics Markets Report 4Reportlinker Adds Stem Cell Therapeutics Markets Report 5Reportlinker Adds Stem Cell Therapeutics Markets Report 6Reportlinker Adds Stem Cell Therapeutics Markets Report 7Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 2Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 3
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Louisiana, US - Alligators display the same loyalty to ... in Molecular Ecology . The ten-year-study by scientists from ... of females chose to remain with their partner, often for ... Ruth Elsey, Tracey Tuberville and Stacey Lance, spent a decade ...
... in Spanish . , Individuals who follow ... grains and fish- appear less likely to develop depression, according ... the October issue of Archives of General Psychiatry . ... to be lower in Mediterranean than Northern European countries, according ...
... , This release is available in German . ... selectively transcribe parts of the DNA that makes up its genome ... proteins synthesized by a cell in turn determines its structure and ... crucial that the appropriate stretches of DNA are transcribed in each ...
Cached Biology News:Loyal alligators display the mating habits of birds 2Mediterranean diet associated with reduced risk of depression 2How RNA polymerase II gets the go-ahead for gene transcription 2How RNA polymerase II gets the go-ahead for gene transcription 3
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: